Our Mission
To Bring Those Tracking the Weight Loss Market The Latest Industry News and Company Developments, Marketdata Commentary and Opinions. To Provide An Ongoing Forum for Discussion and Feedback for Those Working in The Weight Loss Field.
The Most Comprehensive Study About The U.S. Weight Loss Market–Since 1989
The U.S. Weight Loss & Diet Control Market
March 2023 427 Pages 160 tables/charts Price: $1,995
The $75 billion U.S. weight loss market grew nearly 15% last year from the depressed level of 2020. Most segments of the market have recovered from the Covid-19 pandemic and recession. The big story of 2022 has been the soaring demand for new obesity drugs such as Wegovy and Saxenda, with more new drugs coming soon. The market may be entering a new era of medical approaches. Even Weight Watchers is now providing a medical plan.
The frozen diet entrees market and diet soft drinks have shown surprising strength, but the health clubs industry was devasted by the pandemic and emerges as a smaller sector. Supply chain disruptions affected the MLM market for meal replacements into 2021 and 2022, tamping down growth for Herbalife and Medifast. The ranks of commercial weight loss centers have been thinned out, and chains had to pivot to virtual client meetings and drop shipping of
products.
Do-it-yourself plans still abound as consumers use free diet & fitness apps. Many untapped niches still exist. This is a completely revised and updated analysis of Marketdata’s best-selling biennial study about the U.S. weight loss market. This is the most comprehensive investigation of the U.S. weight loss market published by anyone worldwide.
Covered… dollar value & growth rates of all major weight loss market segments (early 1980s to 2022 and 2023 & 2027 forecasts), latest market trends and developments, status reports for: diet soft drinks, artificial sweeteners, health clubs, commercial diet center chains, multi-level marketing diet plans, retail meal replacements & weight loss supplements, medical programs (weight loss surgery, MDs, hospitals/clinic programs, Rx diet drugs, bariatricians, VLCD programs), low-cal frozen entrees, and the diet books & exercise DVDs market.
New for this edition:
- Effects of the Pandemic on operations & revenues for all market segments, analysis of the recovery
- How dieter behavior changed with the pandemic
- The skyrocketing market for Rx obesity drugs and MD programs
- 2022 market performance, 2023 & 2027 Forecasts
- The most popular diets today
- Ranking of the leading competitor companies
- Outlook for the 2023 diet season
- Why MLM is a major force in meal replacements sales, tough year in 2022
- The franchising slowdown.
Also included: 34-year revenue analysis of the market through past recessions and fad diet cycles, comprehensive dieter demographics, weight loss center franchising, and extensive national/state commercial centers’ operating ratios. Rankings & revenues of top commercial chains, brand sales, and a Reference Directory. Contains 34 in-depth competitor profiles for: Weight Watchers, Jenny Craig, NutriSystem, Medifast, Herbalife, Noom, Slim-Fast, Atkins Nutritionals, HMR, Optifast, Robard, Lindora Clinics, Slimgenics, Ideal Protein, Profile by Sanford, BeachBody, Metabolic Research, Smart For Life, Medi-Weightloss, Centers for Medical Weight Loss, Nuviva, JumptStart MD, Dr. G’s, more.
Report also sold by individual chapters at lower price. $99 Overview available.
Latest News
Weight Loss Pills Are On The Horizon
Sept. 23, 2025 Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily 25-milligram semaglutide pill can trigger significant weight loss. “We all knew this was coming, and we all feel that it could potentially be a game changer in terms of adopting these GLP-1s across the board,” Dr. Armando Castro-Tie — a senior vice president and physician executive at Northwell Health, who was not involved in this
Pfizer to Buy Weight-Loss Drug Developer Metsera
Sept. 23, 2025 Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that provides a re-entry for the company into the market for obesity drugs. Pfizer on Monday said it will pay an initial $47.50 a share, or about $4.9 billion, for Metsera, a nearly 43% premium to Friday’s closing price of $33.32 for the company. The deal is expected to close by the end of the year, and includes up to
Keto Diet Is On The Decline
Sept. 12, 2025 According to an article by Food Navigator, the ketogenic diet, popular since the 1990s, is in decline, faced by consumer fatigue over restrictive requirements and strong competition from the GLP-1 medications. Analysts at Tastewise say that social mentions of keto dropped 18% by mid-year 2025 versus the prior year. Keto’s complex and restrictive regimen, including tracking macros and banning entire food groups, is to blame. Keto as a diet plan reached a cultural awareness peak in 2021-2022
FDA Tightens Oversight of GLP-1 Ingredients Imports
Sept. 9, 2025 According to Reuters, “The U.S. Food and Drug Administration is tightening oversight of imports of GLP-1 drug ingredients, used for weight loss and diabetes, amid concerns that many of the items may be adulterated and pose a safety risk. The move comes as the FDA cracks down on unapproved compounded drugs, which had filled the gap during shortages of patented treatments. Soaring demand for obesity drugs sold by Novo Nordisk and Eli Lilly has fueled a booming
Marketdata weight loss reports have been quoted by..
